Want to join the conversation?
$STJ 2Q15 Call: Neuromodulation product sales in the Q215 were $118MM, which included $7MM of unfavorable foreign currency translations. On a constant currency basis, neuromodulation products sales for the Q215 increased 17%. We continue to expect full year 2015 constant currency neuromodulation product sales growth to be in the range of 13% to 15%
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?